Skip to Content

Merck spends $11.5B for Acceleron, possible blockbuster drug

By TOM MURPHY
AP Health Writer

Merck will spend about $11.5 billion to buy Acceleron Pharma and its potential treatment for high blood pressure in vessels that connect the lungs and heart. The drugmaker said Thursday that it will pay $180 per share in cash for Acceleron in a deal expected to close in the fourth quarter.  Acceleron is running late-stage studies of a potential treatment for patients with life-threatening pulmonary arterial hypertension. Merck executives told analysts Thursday that the drug has multi-billion dollar peak sales potential. They hope to launch it in 2024 or 2025. 

Article Topic Follows: AP National Business

Jump to comments ↓

Author Profile Photo

The Associated Press

BE PART OF THE CONVERSATION

News Channel 3-12 is committed to providing a forum for civil and constructive conversation.

Please keep your comments respectful and relevant. You can review our Community Guidelines by clicking here

If you would like to share a story idea, please submit it here.

Skip to content